The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Role of AMP-activated protein kinase in mechanism of metformin action
Open accessAbstract
Metformin is a widely used drug for treatment of type 2 diabetes with no defined cellular mechanism of action. Its glucose-lowering effect results from decreased hepatic glucose production and increased glucose utilization. Metformin's beneficial effects on circulating lipids have been linked to reduced fatty liver. AMP-activated protein kinase (AMPK) is a major cellular regulator of lipid and glucose metabolism. Here we report that metformin activates AMPK in hepatocytes; as a result, acetyl-CoA carboxylase (ACC) activity is reduced, fatty acid oxidation is induced, and expression of lipogenic enzymes is suppressed. Activation of AMPK by metformin or an adenosine analogue suppresses expression of SREBP-1, a key lipogenic transcription factor. In metformin-treated rats, hepatic expression of SREBP-1 (and other lipogenic) mRNAs and protein is reduced; activity of the AMPK target, ACC, is also reduced. Using a novel AMPK inhibitor, we find that AMPK activation is required for metformin's inhibitory effect on glucose production by hepatocytes. In isolated rat skeletal muscles, metformin stimulates glucose uptake coincident with AMPK activation. Activation of AMPK provides a unified explanation for the pleiotropic beneficial effects of this drug; these results also suggest that alternative means of modulating AMPK should be useful for the treatment of metabolic disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“However, being a nonspecific inhibitor of oxidative phosphorylation [674, 675]”
From Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition) 1 (2021) · cites this paper as [675]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredIn the citing paper
“AMPK is activated through metabolic stress and acts as a cellular regulator of lipid and glucose metabolism (102, 103).”
From A Critical Review of the Evidence That Metformin Is a Putative Anti-Aging Drug That Enhances Healthspan and Extends Lifespan (2021) · cites this paper as [102]
In the citing paper
“It is also activated by the antidiabetic drugs metformin and rosiglitazone (21-23), and by the adipocyte-derived hormones leptin and adiponectin (24, 25).”
From CBS domains form energy-sensing modules whose binding of adenosine ligands is disrupted by disease mutations (2004) · cites this paper as [21]
In the citing paper
“it has even been shown to stimulate autophagy by an AMP-independent mechanism [675, 678]”
From Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition) 1 (2021) · cites this paper as [675]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
OWEN, M. R., DORAN, E., & HALESTRAP, A. P. (2000) · Biochemical Journal · doi:10.1042/bj3480607 · Cited by 2,157
The Mitochondrial Carnitine Palmitoyltransferase System — From Concept to Molecular Analysis
McGarry, J. D., & Brown, N. F. (1997) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1997.00001.x · Cited by 1,616 · cited 1×
“Malonyl-CoA is an initial substrate for de novo fatty acid biosynthesis, and it serves as a potent inhibitor of carnitine palmitoyl transferase I (CPT-I), a rate-limiting step for fatty acid oxidation (34).”
BackgroundEl-Mir, M.-Y., Nogueira, V., Fontaine, E., Avéret, N., Rigoulet, M., & Leverve, X. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.1.223 · Cited by 1,399
The AMP‐Activated Protein Kinase: Fuel Gauge of the Mammalian Cell?
Hardie, D. G., & Carling, D. (1997) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1997.00259.x · Cited by 1,317
Metabolic effects of metformin in non-insulin-dependent diabetes mellitus
Stumvoll, M., Nurjhan, N., Perriello, G., Dailey, G., & Gerich, J. E. (1995) · New England Journal of Medicine · doi:10.1056/nejm199508313330903 · Cited by 1,148
Mechanism by which metformin reduces glucose production in type 2 diabetes.
Hundal, R. S., Krssak, M., Dufour, S., Laurent, D., Lebon, V, Chandramouli, V, Inzucchi, S. E., Schumann, W. C., Petersen, K. F., Landau, B. R., et al. (2000) · Diabetes · doi:10.2337/diabetes.49.12.2063 · Cited by 1,052 · cited 2×
“It is believed that metformin-mediated inhibition of hepatic glucose production (HGP) plays a major role in its glucose-lowering efficacy (2, 3, 6).”
BackgroundMerrill, G. F., Kurth, E. J., Hardie, D. G., & Winder, W. W. (1997) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1997.273.6.e1107 · Cited by 1,048
AMP-activated protein kinase, a metabolic master switch: possible roles in Type 2 diabetes
Winder, W. W., & Hardie, D. G. (1999) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1999.277.1.e1 · Cited by 1,000
Shimomura, I., Matsuda, M., Hammer, R. E., Bashmakov, Y. K., Brown, M. S., & Goldstein, J. L. (2000) · Molecular Cell · doi:10.1016/s1097-2765(05)00010-9 · Cited by 860
Hayashi, T., Hirshman, M. F., Kurth, E. J., Winder, W. W., & Goodyear, L. J. (1998) · Diabetes · doi:10.2337/diab.47.8.1369 · Cited by 774
Self-citation
Flagged first, then by citations
Research works printed but not linked: 11
- Schafer, 1983, Diabete Metab, 9, 148
- 10.1210/en.131.3.1165 · DOI
- Winder, 1999, Am J Physiol, 277, E1
- Merrill, 1997, Am J Physiol, 273, E1107
- Goodyear, 2000, Exerc Sport Sci Rev, 28, 113
- Cusi, 1998, Diabetes Reviews, 6, 89
- Wiernsperger, 1999, Diabetes Metab, 25, 110
- Hermann, 1979, Diabete Metab, 5, 233
- Sterne, 1979, Research Clinical Forums, 1, 13
- 10.1042/0264-6021:3480607 · DOI · Paper page
- 10.1016/S1097-2765(00)00009-5 · DOI
Cited by
Sorted by citations
Items 101–200 of 1,066
Scott, J. W., Hawley, S. A., Green, K. A., Anis, M., Stewart, G., Scullion, G. A., Norman, D. G., & Hardie, D. G. (2004) · Journal of Clinical Investigation · doi:10.1172/jci19874 · Cited by 754
Mitochondrial dysfunction in Nash: causes, consequences and possible means to prevent it
Begriche, K., Igoudjil, A., Pessayre, D., & Fromenty, B. (2006) · Mitochondrion · doi:10.1016/j.mito.2005.10.004 · Cited by 753
The Ancient Drug Salicylate Directly Activates AMP-Activated Protein Kinase
Hawley, S. A., Fullerton, M. D., Ross, F. A., Schertzer, J. D., Chevtzoff, C., Walker, K. J., Peggie, M. W., Zibrova, D., Green, K. A., Mustard, K. J., et al. (2012) · Science · doi:10.1126/science.1215327 · Cited by 760
Metformin: update on mechanisms of action and repurposing potential
Foretz, M., Guigas, B., & Viollet, B. (2023) · Nature Reviews Endocrinology · doi:10.1038/s41574-023-00833-4 · Cited by 791
Kolluru, G. K., Bir, S. C., & Kevil, C. G. (2012) · International Journal of Vascular Medicine · doi:10.1155/2012/918267 · Cited by 752
The link between abdominal obesity, metabolic syndrome and cardiovascular disease
Ritchie, S. A., & Connell, J. M. C. (2006) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2006.07.005 · Cited by 746
The biphasic function of microglia in ischemic stroke
Ma, Y., Wang, J., Wang, Y., & Yang, G.-Y. (2017) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2016.01.005 · Cited by 655
ATM signals to TSC2 in the cytoplasm to regulate mTORC1 in response to ROS
Alexander, A., Cai, S.-L., Kim, J., Nanez, A., Sahin, M., MacLean, K. H., Inoki, K., Guan, K.-L., Shen, J., Person, M. D., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0913860107 · Cited by 717
AMPK: a key regulator of energy balance in the single cell and the whole organism
Hardie, D. G. (2008) · International Journal of Obesity · doi:10.1038/ijo.2008.116 · Cited by 727
Anti-inflammatory effects of metformin irrespective of diabetes status
Cameron, A. R., Morrison, V. L., Levin, D., Mohan, M., Forteath, C., Beall, C., McNeilly, A. D., Balfour, D. J. K., Savinko, T., Wong, A. K. F., et al. (2016) · Circulation Research · doi:10.1161/circresaha.116.308445 · Cited by 704
Hawley, S. A., Gadalla, A. E., Olsen, G. S., & Hardie, D. G. (2002) · Diabetes · doi:10.2337/diabetes.51.8.2420 · Cited by 696
Understanding the glucoregulatory mechanisms of metformin in type 2 diabetes mellitus
Foretz, M., Guigas, B., & Viollet, B. (2019) · Nature Reviews Endocrinology · doi:10.1038/s41574-019-0242-2 · Cited by 686
Recent insights into hepatic lipid metabolism in non-alcoholic fatty liver disease (NAFLD)
Musso, G., Gambino, R. J., & Cassader, M. (2008) · Progress in Lipid Research · doi:10.1016/j.plipres.2008.08.001 · Cited by 691
Onken, B., & Driscoll, M. (2010) · PLoS ONE · doi:10.1371/journal.pone.0008758 · Cited by 671
Heart Failure in Type 2 Diabetes Mellitus
Kenny, H., & Abel, E. D. (2019) · Circulation Research · doi:10.1161/circresaha.118.311371 · Cited by 682
Zang, M., Xu, S., Maitland, K. A., Zuccollo, A., Hou, X., Jiang, B., Wierzbicki, M., Verbeuren, T. J., & Cohen, R. A. (2006) · Diabetes · doi:10.2337/db05-1188 · Cited by 672
Musso, G., Cassader, M., Rosina, F., & Gambino, R. (2012) · Diabetologia · doi:10.1007/s00125-011-2446-4 · Cited by 661
Addressing the Role of Obesity in Endometrial Cancer Risk, Prevention, and Treatment
Onstad, M. A., Schmandt, R. E., & Lu, K. H. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.69.4638 · Cited by 667
PGC-1 α , Inflammation, and Oxidative Stress: An Integrative View in Metabolism
Rius‐Pérez, S., Torres-Cuevas, I., Millán, I., Ortega, Á., & Pérez, S. (2020) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2020/1452696 · Cited by 671
Update on the treatment of type 2 diabetes mellitus
Marín-Peñalver, J. J., Martín-Timón, I., Sevillano-Collantes, C., & Cañizo-Gómez, F. J. D. (2016) · World Journal of Diabetes · doi:10.4239/wjd.v7.i17.354 · Cited by 647
LKB1 and AMP-activated protein kinase control of mTOR signalling and growth
Shaw, R. J. (2009) · Acta Physiologica · doi:10.1111/j.1748-1716.2009.01972.x · Cited by 644
Low-dose metformin targets the lysosomal AMPK pathway through PEN2
Ma, T., Tian, X., Zhang, B., Li, M., Wang, Y., Yang, C., Wu, J., Wei, X., Qu, Q., Yu, Y., et al. (2022) · Nature · doi:10.1038/s41586-022-04431-8 · Cited by 644
Adiponectin: A Novel Adipokine Linking Adipocytes and Vascular Function
Goldstein, B. J., & Scalia, R. G. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0518 · Cited by 647
Metabolic Syndrome: A Clinical and Molecular Perspective
Moller, D. E., & Kaufman, K. D. (2004) · Annual Review of Medicine · doi:10.1146/annurev.med.56.082103.104751 · Cited by 636
Self-citationZhang, X., Zhao, Y., Xu, J., Xue, Z., Zhang, M., Pang, X., Zhang, X., & Zhao, L. (2015) · Scientific Reports · doi:10.1038/srep14405 · Cited by 630
Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1
Ben Sahra, I., Regazzetti, C., Robert, G., Laurent, K., Le Marchand-Brustel, Y., Auberger, P., Tanti, J.-F., Giorgetti-Peraldi, S., & Bost, F. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-1769 · Cited by 616
AMPK as a Therapeutic Target for Treating Metabolic Diseases
Day, E. A., Ford, R. J., & Steinberg, G. R. (2017) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2017.05.004 · Cited by 630
An Emerging Role of mTOR in Lipid Biosynthesis
Laplante, M., & Sabatini, D. M. (2009) · Current Biology · doi:10.1016/j.cub.2009.09.058 · Cited by 642
Dietary polyphenols as potential nutraceuticals in management of diabetes: a review
Bahadoran, Z., Mirmiran, P., & Azizi, F. (2013) · Journal of Diabetes & Metabolic Disorders · doi:10.1186/2251-6581-12-43 · Cited by 601
Activation of yeast Snf1 and mammalian AMP-activated protein kinase by upstream kinases
Hong, S. P., Leiper, F. C., Woods, A., Carling, D., & Carlson, M. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1533136100 · Cited by 617
Structural basis for AMP binding to mammalian AMP-activated protein kinase
Xiao, B., Heath, R., Saiu, P., Leiper, F. C., Leone, P., Jing, C., Walker, P. A., Haire, L., Eccleston, J. F., Davis, C. T., et al. (2007) · Nature · doi:10.1038/nature06161 · Cited by 591
Saturated Fatty Acids Synergize with Elevated Glucose to Cause Pancreatic β-Cell Death
El-Assaad, W., Buteau, J., Peyot, M., Nolan, C. J., Roduit, R., Hardy, S., Joly, E. C., Dbaibo, G. S., Rosenberg, L. C., & Prentki, M. (2003) · Endocrinology · doi:10.1210/en.2003-0410 · Cited by 586
Targeting immunometabolism as an anti-inflammatory strategy
Pålsson‐McDermott, E. M., & O'Neill, L. A. J. (2020) · Cell Research · doi:10.1038/s41422-020-0291-z · Cited by 590
BMP8B Increases Brown Adipose Tissue Thermogenesis through Both Central and Peripheral Actions
Whittle, A. J., Carobbio, S., Martins, L., Slawik, M., Hondares, E., Vázquez, M. J., Morgan, D., Csikasz, R. I., Gallego, R., Rodriguez-Cuenca, S., et al. (2012) · Cell · doi:10.1016/j.cell.2012.02.066 · Cited by 573
Cellular energy stress induces AMPK-mediated regulation of YAP and the Hippo pathway
Mo, J.-S., Meng, Z., Kim, Y. C., Park, H. W., Hansen, C. G., Kim, S., Lim, D.-S., & Guan, K.-L. (2015) · Nature Cell Biology · doi:10.1038/ncb3111 · Cited by 557
Corradetti, M. N., Inoki, K., Bardeesy, N. M., DePinho, R. A., & Guan, K. (2004) · Genes & Development · doi:10.1101/gad.1199104 · Cited by 556
Immune-mediated antitumor effect by type 2 diabetes drug, metformin
Eikawa, S., Nishida, M., Mizukami, S., Yamazaki, C., Nakayama, E., & Udono, H. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1417636112 · Cited by 563
Fibroblast growth factor 21 regulates energy metabolism by activating the AMPK–SIRT1–PGC-1α pathway
Chau, M. D. L., Gao, J., Yang, Q., Wu, Z., & Gromada, J. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1006962107 · Cited by 557
Metformin as adjunct antituberculosis therapy
Singhal, A., Jie, L., Kumar, P., Hong, G. S., Leow, M. K.-S., Paleja, B., Tsenova, L., Kurepina, N., Chen, J., Zolezzi, F., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3009885 · Cited by 547
Crucial role of a long-chain fatty acid elongase, Elovl6, in obesity-induced insulin resistance
Matsuzaka, T., Shimano, H., Yahagi, N., Kato, T., Atsumi, A., Yamamoto, T., Inoue, N., Ishikawa, M., Okada, S., Ishigaki, N., et al. (2007) · Nature Medicine · doi:10.1038/nm1662 · Cited by 557
Metformin and Its Benefits for Various Diseases
Lv, Z., & Guo, Y. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00191 · Cited by 563
PI3K/AKT, MAPK and AMPK signalling: protein kinases in glucose homeostasis
Schultze, S. M., Hemmings, B. A., Nießen, M., & Tschopp, O. (2012) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399411002109 · Cited by 553
Deficiency of LKB1 in skeletal muscle prevents AMPK activation and glucose uptake during contraction
Sakamoto, K., McCarthy, A., Smith, D. P., Green, K. A., Hardie, D. G., Ashworth, A., & Alessi, D. R. (2005) · The EMBO Journal · doi:10.1038/sj.emboj.7600667 · Cited by 552
Sahra, I. B., Laurent, K., Giuliano, S., Larbret, F., Ponzio, G., Gounon, P., MARCHAND‐BRUSTEL, Y. L., Giorgetti‐Peraldi, S., Cormont, M., Bertolotto, C., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-2782 · Cited by 549
Turner, N., Li, J.-Y., Gosby, A., To, S. W. C., Cheng, Z., Miyoshi, H., Taketo, M. M., Cooney, G. J., Kraegen, E. W., James, D. E., et al. (2008) · Diabetes · doi:10.2337/db07-1552 · Cited by 535
Dietary anthocyanin‐rich plants: Biochemical basis and recent progress in health benefits studies
Tsuda, T. (2011) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201100526 · Cited by 535
Rapalogs and mTOR inhibitors as anti-aging therapeutics
Lamming, D. W., Ye, L., Sabatini, D. M., & Baur, J. A. (2013) · Journal of Clinical Investigation · doi:10.1172/jci64099 · Cited by 531
Non-alcoholic fatty liver disease and diabetes
Hazlehurst, J., Woods, C. P., Marjot, T., Cobbold, J., & Tomlinson, J. (2016) · Metabolism · doi:10.1016/j.metabol.2016.01.001 · Cited by 541
AMPK and cell proliferation – AMPK as a therapeutic target for atherosclerosis and cancer
Motoshima, H., Goldstein, B. J., Igata, M., & Araki, E. (2006) · The Journal of Physiology · doi:10.1113/jphysiol.2006.108324 · Cited by 543
Viollet, B., Foretz, M., Guigas, B., Horman, S., Dentin, R., Bertrand, L., Hue, L., & Andréelli, F. (2006) · The Journal of Physiology · doi:10.1113/jphysiol.2006.108506 · Cited by 543
Tiikkainen, M., Häkkinen, A.-M., Korsheninnikova, E., Nyman, T., Mäkimattila, S., & Yki-Järvinen, H. (2004) · Diabetes · doi:10.2337/diabetes.53.8.2169 · Cited by 524
Alimova, I. N., Liu, B., Fan, Z., Edgerton, S. M., Dillon, T., Lind, S. E., & Thor, A. D. (2009) · Cell Cycle · doi:10.4161/cc.8.6.7933 · Cited by 523
Thiazolidinediones, Like Metformin, Inhibit Respiratory Complex I
Brunmair, B., Staniek, K., Gras, F., Scharf, N., Althaym, A., Clara, R., Roden, M., Gnaiger, E., Nohl, H., Waldhäusl, W., et al. (2004) · Diabetes · doi:10.2337/diabetes.53.4.1052 · Cited by 521
AMPK: A Key Sensor of Fuel and Energy Status in Skeletal Muscle
Hardie, D. G., & Sakamoto, K. (2006) · Physiology · doi:10.1152/physiol.00044.2005 · Cited by 536
Kim, M., Park, J., NamKoong, C., Jang, P., Ryu, J., Song, H.-S., Yun, J.-Y., Nam‐Goong, I. S., Ha, J., Park, I.-S., et al. (2004) · Nature Medicine · doi:10.1038/nm1061 · Cited by 527
Novel concepts in insulin regulation of hepatic gluconeogenesis
Barthel, A., & Schmoll, D. (2003) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00253.2003 · Cited by 525
Mitochondria—A Nexus for Aging, Calorie Restriction, and Sirtuins?
Guarente, L. (2008) · Cell · doi:10.1016/j.cell.2008.01.007 · Cited by 513
Estrogen Regulation of Adiposity and Fuel Partitioning
D'Eon, T. M., Souza, S. C., Aronovitz, M. J., Obin, M. S., Fried, S. K., & Greenberg, A. S. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m507339200 · Cited by 515
Investigating Metformin for Cancer Prevention and Treatment: The End of the Beginning
Pollak, M. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0263 · Cited by 512
Kukidome, D., Nishikawa, T., Sonoda, K., Imoto, K., Fujisawa, K., Yano, M., Motoshima, H., Taguchi, T., Matsumura, T., & Araki, E. (2006) · Diabetes · doi:10.2337/diabetes.55.01.06.db05-0943 · Cited by 504
AMPK: a metabolic gauge regulating whole-body energy homeostasis
Lage, R., Diéguez, C., Vidal‐Puig, A., & López, M. (2008) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2008.09.007 · Cited by 512
Treatment of nonalcoholic fatty liver disease: role of AMPK
Smith, B. K., Marcinko, K., Desjardins, E. M., Lally, J., Ford, R. J., & Steinberg, G. R. (2016) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00225.2016 · Cited by 509
The MAPK and AMPK signalings: interplay and implication in targeted cancer therapy
Yuan, J., Dong, X., Yap, J., & Hu, J. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00949-4 · Cited by 516
The AMP-activated protein kinase α2 catalytic subunit controls whole-body insulin sensitivity
Viollet, B., Andreelli, F., Jørgensen, S. B., Perrin, C., Geloen, A., Flamez, D., Mu, J., Lenzner, C., Baud, O., Bennoun, M., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci16567 · Cited by 499
Oral antihyperglycemic therapy for type 2 diabetes mellitus
CHENG, A. Y. Y. (2005) · Canadian Medical Association Journal · doi:10.1503/cmaj.1031414 · Cited by 512
Metformin pathways: pharmacokinetics and pharmacodynamics
Gong, L., Goswami, S., Giacomini, K. M., Altman, R. B., & Klein, T. E. (2012) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e3283559b22 · Cited by 495
Metformin in cancer therapy: a new perspective for an old antidiabetic drug?
Ben Sahra, I., Le Marchand-Brustel, Y., Tanti, J.-F., & Bost, F. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-1186 · Cited by 493
Xie, Z., Lau, K., Eby, B., Lozano, P., He, C., Pennington, B., Li, H., Rathi, S., Dong, Y., Tian, R., et al. (2011) · Diabetes · doi:10.2337/db10-0351 · Cited by 490
Hattori, Y., Suzuki, K., Hattori, S., & Kasai, K. (2006) · Hypertension · doi:10.1161/01.hyp.0000221429.94591.72 · Cited by 487
Viollet, B., Guigas, B., Leclerc, J., Hébrard, S., Lantier, L., Mounier, R., Andréelli, F., & Foretz, M. (2009) · Acta Physiologica · doi:10.1111/j.1748-1716.2009.01970.x · Cited by 498
Molecular mechanism of action of metformin: old or new insights?
Rena, G., Pearson, E. R., & Sakamoto, K. (2013) · Diabetologia · doi:10.1007/s00125-013-2991-0 · Cited by 479
He, L., Sabet, A., Djedjos, S., Miller, R., Sun, X., Hussain, M. A., Radovick, S., & Wondisford, F. E. (2009) · Cell · doi:10.1016/j.cell.2009.03.016 · Cited by 486
Glucose-regulated phosphorylation of TET2 by AMPK reveals a pathway linking diabetes to cancer
Wu, D., Hu, D., Chen, H., Shi, G., Fetahu, I. S., Wu, F., Rabidou, K., Fang, R., Tan, L., Xu, S., et al. (2018) · Nature · doi:10.1038/s41586-018-0350-5 · Cited by 477
Self-citationFoufelle, F., & Ferré, P. (2002) · Biochemical Journal · doi:10.1042/bj20020430 · Cited by 496
Activation of the AMP-activated Protein Kinase by the Anti-diabetic Drug Metformin in Vivo
Zou, M., Kirkpatrick, S. S., Davis, B. J., Nelson, J. S., Wiles, W. G., Schlattner, U., Neumann, D., Brownlee, M., Freeman, M. B., & Goldman, M. H. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m404421200 · Cited by 480
RetractedThe role of AMP-activated protein kinase in the action of ethanol in the liver
You, M., Matsumoto, M., Pacold, C. M., Cho, W. K., & Crabb, D. W. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.09.049 · Cited by 469
Nair (2005) · doi:10.1093/ajcn/81.5.953 · Cited by 469
Sirtuins as potential targets for metabolic syndrome
Guarente, L. (2006) · Nature · doi:10.1038/nature05486 · Cited by 468
Hypothalamic Fatty Acid Metabolism Mediates the Orexigenic Action of Ghrelin
López, M., Lage, R., Saha, A. K., Pérez–Tilve, D., Vazquez, M. J., Varela, L., Sangiao‐Alvarellos, S., Tovar, S. A., Raghay, K., Rodríguez‐Cuenca, S., et al. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2008.03.006 · Cited by 486
Sun, Y., Shi, H., Yin, S., Ji, C., Zhang, X., Zhang, B., Wu, P., Shi, Y., Mao, F., Yan, Y., et al. (2018) · ACS Nano · doi:10.1021/acsnano.7b07643 · Cited by 468
Davis, B. J., Xie, Z., Viollet, B., & Zou, M. (2006) · Diabetes · doi:10.2337/diabetes.55.02.06.db05-1064 · Cited by 465
AMP-activated Protein Kinase and the Regulation of Autophagic Proteolysis
Meley, D., Bauvy, C., Houben-Weerts, J. H. P. M., Dubbelhuis, P. F., Helmond, M. T. J., Codogno, P., & Meijer, A. J. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m605488200 · Cited by 419
Wu, X., Motoshima, H., Mahadev, K., Stalker, T. J., Scalia, R. G., & Goldstein, B. J. (2003) · Diabetes · doi:10.2337/diabetes.52.6.1355 · Cited by 473
Mitochondrial Diseases: Hope for the Future
Russell, O. M., Gorman, G. S., Lightowlers, R. N., & Turnbull, D. M. (2020) · Cell · doi:10.1016/j.cell.2020.02.051 · Cited by 480
AMPK: A Target for Drugs and Natural Products With Effects on Both Diabetes and Cancer
Hardie, D. G. (2013) · Diabetes · doi:10.2337/db13-0368 · Cited by 458
Campbell, J. M., Bellman, S. M., Stephenson, M. D., & Lisy., K. (2017) · Ageing Research Reviews · doi:10.1016/j.arr.2017.08.003 · Cited by 455
AMP kinase and malonyl-CoA: targets for therapy of the metabolic syndrome
Ruderman, N., & Prentki, M. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1344 · Cited by 451
Metformin and inflammation: its potential Beyond glucose-lowering effect
Saisho, Y. (2015) · Endocrine, Metabolic & Immune Disorders-Drug Targets · doi:10.2174/1871530315666150316124019 · Cited by 450
Zang, M., Zuccollo, A., Hou, X., Nagata, D., Walsh, K. X., Herscovitz, H., Brecher, P. I., Ruderman, N. B., & Cohen, R. A. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m408149200 · Cited by 455
Metformin Action: Concentrations Matter
He, L., & Wondisford, F. E. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2015.01.003 · Cited by 448
Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes
The GoDARTS and UKPDS Diabetes Pharmacogenetics Study Group (2010) · Nature Genetics · doi:10.1038/ng.735 · Cited by 452
AMPK activation: a therapeutic target for type 2 diabetes?
Saha, A. K., Coughlan, K. A., Valentine, R. J., & Ruderman, N. B. (2014) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s43731 · Cited by 458
Takikawa, M., Inoue, S., Horio, F., & Tsuda, T. (2010) · Journal of Nutrition · doi:10.3945/jn.109.118216 · Cited by 448
Mechanism of Action of A-769662, a Valuable Tool for Activation of AMP-activated Protein Kinase
Göransson, O., McBride, A., Hawley, S. A., Ross, F. A., Shpiro, N., Foretz, M., Viollet, B., Hardie, D. G., & Sakamoto, K. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m706536200 · Cited by 452
Metformin Improves Mitochondrial Respiratory Activity through Activation of AMPK
Wang, Y., An, H., Liu, T., Qin, C., Sesaki, H., Guo, S., Radovick, S., Hussain, M., Maheshwari, A., Wondisford, F. E., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.09.070 · Cited by 432
“Metformin was reported to activate AMPK (Hawley et al., 2002; Zhou et al., 2001).”
BackgroundMitochondrial dysfunction in type 2 diabetes mellitus: an organ-based analysis
Pinti, M. V., Fink, G. K., Hathaway, Q. A., Durr, A. J., Kunovac, A., & Hollander, J. M. (2019) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00314.2018 · Cited by 447
Frank, N., Geor, R. J., Bailey, S. R., Durham, A. E., & Johnson, P. J. (2010) · Journal of Veterinary Internal Medicine · doi:10.1111/j.1939-1676.2010.0503.x · Cited by 449
Pathogenesis of steatohepatitis
Day, C. P. (2002) · Best Practice & Research Clinical Gastroenterology · doi:10.1053/bega.2002.0333 · Cited by 434
Metformin Therapy and Risk of Cancer in Patients with Type 2 Diabetes: Systematic Review
Franciosi, M., Lucisano, G., Lapice, E., Strippoli, G. F. M., Pellegrini, F., & Nicolucci, A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0071583 · Cited by 428
Hoffman, N. J., Parker, B. L., Chaudhuri, R., Fisher-Wellman, K. H., Kleinert, M., Humphrey, S. J., Yang, P., Holliday, M., Trefely, S., Fazakerley, D. J., et al. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2015.09.001 · Cited by 426
Metadata
- Authors
- Zhou, G., Myers, R., Li, Y., Chen, Y., Shen, X., Fenyk-Melody, J., Wu, M., Ventre, J., Doebber, T., Fujii, N., Musi, N., Hirshman, M. F., Goodyear, L. J., & Moller, D. E.
- Affiliations
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Corresponding author
- Zhou, Gaochao
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2001-10-15
- Volume
- 108
- Issue
- 8
- Pages
- 1167-1174
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC209533
- OpenAlex
- W2138226825
- Cited by
- 5,652
- References
- 36
- Citations by year
- 2026: 149 · 2025: 182 · 2024: 198 · 2023: 234 · 2022: 270 · 2021: 312 · 2020: 272 · 2019: 310 · 2018: 306 · 2017: 304 · 2016: 296 · 2015: 331 · 2014: 307 · 2013: 295 · 2012: 291
- FWCI
- 26.36
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Natural Antidiabetic Agents Studies
- Keywords
- metformin, AMPK, type 2 diabetes, hepatic glucose production, acetyl-CoA carboxylase, SREBP1, lipogenesis, fatty acid oxidation, glucose uptake, skeletal muscle, hepatic lipid metabolism, AMPK inhibitors
- MeSH terms
- Aminoimidazole Carboxamide, Animals, Diabetes Mellitus, Type 2, DNA-Binding Proteins, Enzyme Activation, Fatty Acids, Glucose, Humans, Hypoglycemic Agents, Male, Metformin, Multienzyme Complexes, Protein Kinases, Pyrazoles, Pyrimidines, Ribonucleotides, RNA, Messenger, Transcription Factors, Gene Expression, Rats, Sprague-Dawley, Protein Serine-Threonine Kinases, Muscle, Skeletal, CCAAT-Enhancer-Binding Proteins, Hepatocytes, Protein Kinase Inhibitors, Rats, Sterol Regulatory Element Binding Protein 1, AMP-Activated Protein Kinases, In Vitro Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review